Online inquiry

IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ14818MR)

This product GTTS-WQ14818MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD70 gene. The antibody can be applied in Autoimmune diseases research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001252.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 970
UniProt ID P32970
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ14818MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ744MR IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AAB-001
GTTS-WQ293MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ5722MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CEA TCB
GTTS-WQ156MR IVTScrip™ mRNA-Anti-EGFR, 1-26/3-67(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA 1-26/3-67
GTTS-WQ10551MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA LY­3074828
GTTS-WQ4466MR IVTScrip™ mRNA-Anti-SLAMF7, BMS-901608(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-901608
GTTS-WQ14231MR IVTScrip™ mRNA-Anti-C5, RG-6107(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RG-6107
GTTS-WQ14955MR IVTScrip™ mRNA-Anti-PDCD1, SHR-1210(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SHR-1210
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW